The activity of fluconazole and amphotericin B against three isolates of Cryptococcus neoformans was evaluated, with fluconazole and amphotericin B MICs of 2.0-4.0 mg/L and 1.0 mg/L respectively, using time-kill curve methods. Fluconazole was fungistatic against all isolates tested (<99.9% decrease in cfu from initial inoculum). The fungistatic activity of fluconazole was not enhanced by increasing the concentration of antifungal in solution. In contrast, amphotericin B was markedly fungicidal ( 99.9% decrease in cfu from initial inoculum). Both the rate and the extent of amphotericin B activity were enhanced when drug concentration was increased.
Introduction
Meningitis secondary to Cryptococcus neoformans is the most common life-threatening fungal infection among AIDS patients and, when untreated, is uniformly fatal among this patient population. When seemingly appropriate antifungal therapy is given, mortality associated with cryptococcal meningitis remains high (5.5-20%). 1, 2 Although the combination of amphotericin B and flucytosine is often the regimen of choice, fluconazole with or without flucytosine is also an effective treatment. 1, 3 There remains a considerable amount of disagreement regarding optimal dosing of these agents in this setting. Doses of 0.3-1.0 mg/kg/day and 200-1000 mg/day have been employed for amphotericin B and fluconazole, respectively. [1] [2] [3] [4] [5] [6] Understanding antifungal pharmacodynamics may help determine optimal dosing. We sought to characterize the relationships between concentrations of fluconazole and amphotericin B and the rate and extent of antifungal activity against C. neoformans in vitro.
Materials and methods

Antifungal agents
Stock solutions of fluconazole (Pfizer, New York, NY, USA) and amphotericin B (Sigma Chemical Co., St Louis, MO, USA) were prepared using RPMI 1640 medium (Sigma) buffered to a pH of 7.0 with 0.165 M morpholine propanesulphonic acid (MOPS) buffer (Sigma) as solvent.
Dimethylsulphoxide (DMSO) was used to aid the solubilization of amphotericin B. DMSO comprised 1% of the total test solution volume. Growth curves were conducted with DMSO at concentrations equal to those present in test solutions to verify that it did not inhibit the growth of test isolates. Stock solutions were stored at 70°C until needed. 
Test isolates
Time-kill curve procedures
Time-kill studies were performed as described previously. 8 Before testing, fungi were subcultured twice on potato dextrose agar plates. Colonies from a 24-48 h culture were suspended in approximately 9 mL of sterile water and adjusted to a 0.5 McFarland turbidity standard. One millilitre of the adjusted fungal suspension was then added to either RPMI medium (control) or a solution of RPMI plus an appropriate amount of antifungal stock solution. These procedures resulted in a starting inoculum of approximately 1 10 5 to 5 10 5 cfu/mL and antifungal concentrations equal to 0.5, 1, 2, 4 and 8 MIC for fluconazole and 0.125, 0.25, 0.5, 1, 2, 4, 8 and 16 MIC for amphotericin B. Test solutions were placed on a shaker and incubated with agitation at 35°C. At predetermined times, 100 L samples were obtained from each solution, serially diluted ten-fold, and a 10 L sample plated on potato dextrose agar for colony counting. When it was expected that there would be 1000 cfu/mL, a 10 L sample was removed from the test solution and plated without dilution. The lower limit of detection of these methods was 100 cfu/mL. Colony counts were recorded following incubation at 35°C for 48-72 h. Kill curve experiments were performed in duplicate.
Analysis
For antifungal carryover studies, mean colony count data for each agent at each multiple of the MIC tested were compared with the control. Significant antifungal carryover was defined as a reduction in mean cfu/mL of 25% compared with the control. 9 Mean colony count data (log 10 cfu/mL) from time-kill studies were plotted as a function of time for each isolate and used to compare the rate and extent of antifungal activity at the various concentrations. The time required to achieve a 99.9% reduction from the initial inoculum was determined for each isolate at the various antifungal concentrations tested. 9 The difference in log 10 cfu/mL between control and experimental samples (expressed as a percent of control) after 6 h was plotted against the multiple of the antifungal MIC. The concentration that resulted in 50% of the maximum effect (EC 50 ) was calculated for each regimen-isolate combination using an inhibitory sigmoid model (WinNonlin, Scientific Consulting, Inc.).
Results
Antifungal susceptibility
Fluconazole MICs were 2 mg/L (strain 853.033) or 4 mg/L (strains 625.012 and 682.027). The MIC of amphotericin B was 1 mg/L for all three of the strains tested. All of the strains were considered susceptible to fluconazole and amphotericin B.
Antifungal carryover
Antifungal carryover was not observed at any of the fluconazole concentrations with either sampling method. Similarly, when a 10 L sample was taken from solutions containing amphotericin B and plated directly for colony count determination, no antifungal carryover was observed. In contrast, a significant carryover effect was noted for isolates 625.012 (27.9% reduction) and 853.033 (46.8% reduction) at an amphotericin B concentration equal to 16 MIC when a sampling volume of 30 L was used. Based upon these findings, 10 L was used as the maximum sampling volume for direct sample plating during time-kill studies.
Time-kill curves
A representative plot of log 10 cfu/mL against time for fluconazole and amphotericin B is presented in the Figure. Fungistatic activity ( 99.9% decrease in cfu/mL from the initial inoculum) was observed with fluconazole against all three isolates. The rate and extent of antifungal activity were not affected by altering the concentration of fluconazole in solution.
In contrast, rapid fungicidal activity ( 99.9% decrease in cfu/mL from the initial inoculum) was noted for each of the cryptococcal isolates when tested against amphotericin B. For strains 682.027 and 853.033, fungistatic activity was noted with concentrations of 0.25 MIC. As the concentration of amphotericin B was increased above 0.25 MIC, rapid fungicidal activity was observed for both isolates. Similarly, for strain 625.012, fungistatic activity was produced by a concentration equal to 0.125 MIC of amphotericin B, whereas rapid fungicidal activity was noted with concentrations of 0.25 MIC. For each of the test isolates, the rate of fungicidal activity increased as the concentration of amphotericin B in solution was increased. The time for each isolate to achieve a 99.9% reduction in cfu/mL from the initial inoculum in the presence of amphotericin B is presented in the Table. The activity of amphotericin B against C. neoformans generally increased as the amphotericin B concentration increased. EC 50 s of 0.21, 0.42 and 0.36 mg/L were calculated for amphotericin B against isolates 625.012, 682.027 and 853.033, respectively. Since the subinhibitory effects of fluconazole were not adequately characterized, similar dose-response curves were not constructed for fluconazole. However, the fungistatic activity exhibited by fluconazole appeared to be independent of the concentration of drug in solution, at least over the multiples of the MIC tested (0.5-8 MIC).
Discussion
In this study, we report the antifungal characteristics of fluconazole and amphotericin B against three clinical isolates of C. neoformans using in-vitro time-kill curve methods. Fluconazole exhibited fungistatic activity at each of the multiples of the MIC tested. Maximum activity was observed at 0.5 MIC and increasing the concentration of fluconazole in solution did not enhance the rate or extent of antifungal activity. Therefore, the activity of fluconazole against C. neoformans seems to be relatively independent of the drug concentration in solution. In contrast, both the rate and extent of fungicidal activity of amphotericin B improved as the concentration of drug in solution was increased. This concentration-dependent effect was most pronounced in terms of the rate of fungicidal activity.
Since this study was conducted in vitro, direct extra- 3 , who observed a mortality rate of 18.2% among 11 patients treated with fluconazole 800-1000 mg daily. These in-vivo findings appear to support our in-vitro data which describe concentration-independent activity for flu c o n a z o l e against C. neoformans.
Various dosing regimens for amphotericin B have been evaluated for the treatment of cryptococcal meningitis in a number of clinical trials.
1,2,4-6 In general, mortality was lower in studies where higher doses of amphotericin B were used. The rate of mortality decreased from 14% (9/63 patients) with a dose of 0.3 mg/kg daily of amphotericin B (no flucytosine) 1 to 5.5% with an amphotericin B dose of 0.7 mg/kg (10/179 with flucytosine and 11/202 without flucytosine) 2 and 3% (1/31 patients) with an amphotericin B dose of 1 mg/kg plus flucytosine 100-150 mg/kg daily. 5 These clinical findings may be explained by the concentration-dependent activity of amphotericin B against C. neoformans which we have described in vitro. Improved outcomes observed with the higher doses of amphotericin B may be linked to a more rapid rate of fungal eradication resulting from increased drug concentrations at the site of infection.
We have described the pharmacodynamic characteristics of fluconazole and amphotericin B against C. neoformans. Fluconazole exhibited concentrationindependent fungistatic activity whereas amphotericin B displayed concentration-dependent fungicidal activity. These data should be considered when formulating dosing regimens for fluconazole and amphotericin B in the treatment of cryptococcal meningitis. 
